| dc.contributor.author | Meghnani, Varsha | |
| dc.description.abstract | The Receptor for Advanced Glycation End Products (RAGE) and its ligands are
expressed in multiple cancer types and are implicated in cancer progression. Our lab has
previously reported higher transcript levels of RAGE and S100B in advanced staged melanoma
patients. The contribution of RAGE in the pathophysiology of melanoma has not been well
studied. Based on previous reports, we hypothesized that RAGE, when over-expressed in
melanoma cells, promotes melanoma progression.
To study the pathogenic role of RAGE in melanoma, a primary melanoma cell line,
WM115, was selected and stably transfected with full length RAGE (FL_RAGE) to generate a
model cell line over-expressing RAGE (WM115_RAGE). WM266, a sister cell line of WM115,
originated from a metastatic tumor of the same patient was used as a metastatic control cell line
in the study. After assessing the expression levels of RAGE in the transfected cells, the influence
of RAGE on their cellular properties was examined. An enhanced motility but suppressed
proliferation of WM115 cells was found after RAGE over-expression, these properties could be
reversed upon suppression of RAGE in these cells.
We next explored the mechanisms of RAGE induced changes in cell proliferation and
migration in WM115_RAGE cells and found a significant upregulation in S100B protein in the
WM115_RAGE melanoma cells compared to the MOCK cells. However, S100B suppression
produced no effect on WM115_RAGE cells motility. Furthermore, expression of tumor
suppressor p53 protein, which is one of the target proteins of S100B, was found to be
significantly reduced in WM115 cells after RAGE over-expression.
We also investigated the effect of RAGE over-expression on melanoma tumor growth
and deciphered the downstream signaling involved. We found a significantly larger tumor growth rate of the WM115_RAGE cells compared to the control cells. S100B, S100A4, S100A6
and S100A10 proteins that are relevant in melanoma pathophysiology, were found to be
upregulated in WM115_RAGE tumors compared to MOCK tumors. Moreover, enhanced AKT
and ERK signal activation was observed in WM115_RAGE tumors as compared to MOCK
tumors. Finally, anti-RAGE antibody treatment significantly suppressed tumor growth, which
could be further enhanced by combining the antibody with the chemotherapeutic drug
dacarbazine. | en_US |
| dc.publisher | North Dakota State University | en_US |
| dc.rights | NDSU Policy 190.6.2 | |
| dc.title | Rage (Receptor for Advanced Glycation End Products) in Melanoma Progression | en_US |
| dc.type | Dissertation | en_US |
| dc.type | Video | en_US |
| dc.date.accessioned | 2018-02-02T19:11:42Z | |
| dc.date.available | 2018-02-02T19:11:42Z | |
| dc.date.issued | 2014 | |
| dc.identifier.uri | https://hdl.handle.net/10365/27415 | |
| dc.title.alternative | Receptor for Advanced Glycation End Products (RAGE) in Melanoma Progression | en_US |
| dc.description.sponsorship | ND-EPSCoR Doctoral Dissertation Assistantship | en_US |
| dc.description.sponsorship | North Dakota State University. College of Health Professions | en_US |
| dc.description.sponsorship | North Dakota State University. College of Pharmacy, Nursing and Allied Sciences | en_US |
| dc.rights.uri | https://www.ndsu.edu/fileadmin/policy/190.pdf | |
| ndsu.degree | Doctor of Philosophy (PhD) | en_US |
| ndsu.college | Health Professions | en_US |
| ndsu.department | School of Pharmacy | en_US |
| ndsu.program | Pharmaceutical Sciences | |
| ndsu.advisor | Leclerc, Estelle | |
